Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.45 |
| ▸ | BTK | Q06187 | 4/20 | 0.45 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | POLQ | O75417 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | HCN1 | O60741 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23623276 | 0.94 | EGFR (0.43) | EGFRBTKKCNK3KCNK9ROCK2 | |
| SCHEMBL23645143 | 0.94 | EGFR (0.43) | EGFRBTKKCNK3KCNK9ROCK2 | |
| SCHEMBL23623496 | 0.93 | EGFR (0.43) | EGFRBTKKCNK3KCNK9TDP1 | |
| SCHEMBL23644237 | 0.93 | EGFR (0.43) | EGFRBTKKCNK3KCNK9ROCK2 | |
| SCHEMBL23623271 | 0.93 | EGFR (0.44) | EGFRBTKKCNK3KCNK9POLQ | |
| SCHEMBL23644241 | 0.93 | EGFR (0.42) | EGFRBTKKCNK3KCNK9ROCK2 | |
| SCHEMBL23623343 | 0.93 | EGFR (0.42) | EGFRBTKKCNK3KCNK9NPC1 | |
| SCHEMBL23645130 | 0.93 | EGFR (0.42) | EGFRBTKKCNK3KCNK9ROCK2 | |
| SCHEMBL23644246 | 0.93 | EGFR (0.42) | EGFRBTKKCNK3KCNK9CNR2 | |
| SCHEMBL23623281 | 0.91 | EGFR (0.43) | EGFRBTKNPC1RAB9APOLQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2022-01-06 | — | — | US | disclosed |
| US-11091447-B2 | UBE2K modulators and methods for their use | BERG LLC (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | THLIVERIS, ANDREW T. | 2021-07-15 | — | — | US | disclosed |
| US-9553272-B2 | Organic electroluminescent device | HODOGAYA CHEMICAL CO., LTD. (JP) | 2017-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091447-B2 | UBE2K modulators and methods for their use | UBE2N, UBE2B, UBE2E1 | EGFR 2809/4885BTK 2701/4885KCNK3 2414/4885 |
| US-20220002255-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | UBE2N, UBE2B, UBE2E1 | EGFR 2809/4885BTK 2701/4885KCNK3 2414/4885 |
| US-20210214320-A1 | UBE2K MODULATORS AND METHODS FOR THEIR USE | UBE2N, UBE2B, UBE2E1 | EGFR 2809/4885BTK 2701/4885KCNK3 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.